Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively.
Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Location: United States, New York
Employees: 51-200
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Sofinnova ... | sofinnova.... |
| - | HBM Partne... | hbmpartner... |
Mentions in press and media 8
| Date | Title | Description | Source |
| 28.10.2022 | Y-mAbs Announces Outcome of FDA Advisory Committee Meeting o... | NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or &q... | einpresswi... |
| 30.08.2022 | Y-mAbs and Takeda Announces Marketing Authorization in Israe... | NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “... | globenewsw... |
| 16.11.2020 | Why contract development and manufacturing for radiopharma m... | One of the fastest-growing segments in the life sciences industry is that of radiopharmaceuticals, o... | medcitynew... |
| 30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY Good morning, Term Sheet readers. Paid Content You can't secure what you can't see ... | fortune.co... |
| 29.11.2017 | YmAbs Closes $30M Extension of Private Equity Financing | Y-mAbs Therapeutics, Inc., a NYC-based immunotherapy company discovering and developing innovative t... | finsmes.co... |
| 27.10.2017 | Term Sheet — Friday, October 27 | BLACK BOX It’s (finally) Friday! Paid Content You can't secure what you can't see From ExtraHop GETT... | fortune.co... |
| 24.10.2017 | YmAbs Raises $50M in Equity Financing | Y-mAbs Therapeutics, Inc., a New York-based immunotherapy company discovering and developing innovat... | finsmes.co... |
| - | Why contract development and manufacturing for radiopharma m... | One of the fastest-growing segments in the life sciences industry is that of radiopharmaceuticals, o... | medcitynew... |